1. Home
  2. BOC vs CGEM Comparison

BOC vs CGEM Comparison

Compare BOC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$12.47

Market Cap

413.9M

Sector

N/A

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$11.30

Market Cap

437.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
CGEM
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
413.9M
437.2M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
BOC
CGEM
Price
$12.47
$11.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$25.00
$27.14
AVG Volume (30 Days)
198.9K
1.2M
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$112,601,970.00
N/A
Revenue This Year
$7.79
N/A
Revenue Next Year
$3.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.22
N/A
52 Week Low
$11.30
$5.68
52 Week High
$15.75
$13.78

Technical Indicators

Market Signals
Indicator
BOC
CGEM
Relative Strength Index (RSI) 45.96 64.86
Support Level $12.13 $8.52
Resistance Level $12.64 $13.33
Average True Range (ATR) 0.43 1.03
MACD 0.04 0.36
Stochastic Oscillator 54.33 66.61

Price Performance

Historical Comparison
BOC
CGEM

About BOC Boston Omaha Corporation

Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: